|
Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Complex I (NADH dehydrogenase, NDU) and complex IV (cytochrome-c-oxidase, COX) of the mitochondrial electron transport chain have been implicated in the pathophysiology of major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ), as well as in neurodegenerative disorders, such as Alzheimer disease (AD) and Parkinson disease (PD).
|
29855563 |
2019 |
|
Abnormal blistering of the skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute episodes of neuropathic symptoms
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute Erythroblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To clarify the importance of CPOX in the regulation of heme biosynthesis in erythroid cells, we established human erythroleukemia K562 cells stably expressing mouse CPOX.
|
11248690 |
2001 |
|
Acute intermittent porphyria
|
0.010 |
Biomarker
|
disease |
BEFREE |
This mechanism may provide a model for phenotype modulation by minor variations in the expression of the wild-type allele in the other three autosomal dominant porphyrias that exhibit incomplete penetrance: acute intermittent porphyria (AIP), variegata porphyria (VP) and hereditary coproporphyria (HC), which are caused by partial deficiencies of hydroxy-methyl bilane synthase (HMBS), protoporphyrinogen oxidase (PPOX) and coproporphyrinogen oxidase (CPO), respectively.
|
14669009 |
2004 |
|
Acute monocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
|
29051180 |
2017 |
|
Acute monocytic leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Our findings are consistent with clinical data, in which CPX-351 activity is retained in high-risk AML patients.
|
28013106 |
2017 |
|
Acute monocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Assessment of Flu-CPX in primary blasts from presentation AML patients (n = 5) demonstrated a more rapid and pronounced potentiation of ara-CTP from CPX-351 than in immortalised cell lines, with 4/5 patients showing significant increases in ara-CTP, notably for those that went on to fail induction and relapse treatment in vivo (n = 3).
|
30119908 |
2018 |
|
Acute monocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia (AML) may be improved by a liposomal encapsulation of cytarabine and daunorubicin (CPX-351).
|
31173485 |
2019 |
|
Acute monocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Likewise, CHK1 inhibition increases the antiproliferative effect of CPX-351 on primary AML specimens ex vivo, offering the possibility that CPX-351 may be well suited to combine with CHK1-targeted agents.
|
30837643 |
2019 |
|
Acute monocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Emerging drug profile: CPX-351 (vyxeos) in AML.
|
31547736 |
2020 |
|
Acute myeloid leukaemia refractory
|
0.020 |
Biomarker
|
disease |
BEFREE |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
|
30119908 |
2018 |
|
Acute myeloid leukaemia refractory
|
0.020 |
Biomarker
|
disease |
BEFREE |
CPX-351 PK data (cytarabine, daunorubicin, and metabolites) from a phase I study of relapsed and refractory AML were used for the analysis.
|
29167924 |
2018 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC).
|
30541745 |
2019 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Future directions include evaluating dose intensification with CPX-351, combining this agent with targeted therapies, and better understanding the mechanism of improved responses in tAML and AML-MRC, two entities that are historically less responsive to cytotoxic agents.
|
29928134 |
2018 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
Biomarker
|
disease |
BEFREE |
CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarabine/daunorubicin therapy.
|
30837643 |
2019 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
Biomarker
|
disease |
BEFREE |
CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.
|
30566230 |
2019 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial.
|
29378418 |
2018 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
Biomarker
|
disease |
BEFREE |
The introduction of CPX-351 offers a novel strategy for treating patients with therapy-related AML or AML with myelodysplasia-related changes; gemtuzumab ozogamicin may become incorporated into standard induction therapy, especially for patients with core-binding factor leukemias; and for older adults, combination therapy with venetoclax may offer a more efficacious strategy than the single-agent regimens previously used.
|
29283906 |
2018 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The approval was based on findings from a multicenter, randomized, open-label, phase III study of CPX-351 Versus 7 + 3 in patients 60-75 years old with newly diagnosed AML-MRC or t-AML.
|
31547736 |
2020 |
|
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
|
0.080 |
Biomarker
|
disease |
BEFREE |
CPX-351 has been approved for adults with newly diagnosed tAML or AML-MRC and has an NCCN category 1 recommendation for induction therapy of patients aged >60 years with high-risk/sAML.
|
31092386 |
2019 |
|
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
The significance of circulating miR-1 in AMI prognosis was assessed using univariate and COX regression analysis.
|
31611081 |
2019 |
|
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
AMI hazard ratios (HR) by SEP and JH were estimated using COX proportional hazard models, before and after adjustment for study covariates.
|
27923154 |
2017 |